NCCN Guidelines® Insights - Ovarian Cancer, Version 1.2019

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living .5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.

Target Audience

This activity is designed to meet the educational needs of physicians, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate into professional practice the updates to the NCCN Guidelines for Ovarian Cancer
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Ovarian Cancer
Additional information
Supporters: 

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Clovis Oncology, Eisai, Genentech, Genomic Health, Inc., Novartis, Taiho Oncology, Inc., and TESARO. This activity is supported by an independent educational grant from AbbVie. This activity is supported by educational funding provided by Amgen. This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
08/10/2019
Course expires: 
08/10/2020
Cost:
$0.00

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.

Individuals Who Provided Content Development and/or Authorship Assistance:
Jamie N. Bakkum-Gamez, MD; Lisa Barroilhet, MD; Kian Behbakht, MD; Andrew Berchuck, MD; Heidi J. Gray, MD; Theresa L. Werner, MD; and Emese Zsiros, MD, PhD, (Panel Members) and Jennifer L. Burns (Guidelines Coordinator, NCCN) and Anita M. Engh, PhD (Oncology Scientist/Medical Writer, NCCN) have no conflicts of interest to disclose.
Deborah K. Armstrong, MD, Panel Chair, has disclosed that she receives grant/research support from AstraZeneca Pharamceuticals LP, Advaxis, Clovis Oncology, Syndax, Tesaro, Inc., and Pfizer Inc.
Ronald D. Alvarez, MD, Panel Vice Chair, has disclosed that he receives grant/research support from Inovia, receives consulting fees/honoraria from Unleash and Vaccitech, and is a scientific advisor for Papivax and Tesaro, Inc.
Lee-may Chen, MD, Panel Member, has disclosed that she receives grant/research support from AstraZeneca Pharmaceuticals LP, Clovis Oncology, and Tesaro, Inc.
Mihaela Cristea, MD, Panel Member, has disclosed that she is a scientific advisor for AstraZeneca Pharmaceuticals LP.
Adam C. ElNaggar, MD, Panel Member, has disclosed that he is a scientific advisor for AstraZeneca Pharmaceuticals LP, Clovis Oncology, Tesaro, Inc., and Caris Life Sciences. He also receives grant/research support from Caris Life Sciences.
David M. Gershenson, MD, Panel Member, has disclosed that he has equity interest/stock options in Biogen Iden, Celgene Corporation, and Johnson & Johnson; receives consulting fees/honoraria from Genentech, Inc., and OncLive; receives grant/research support from Novartis Pharmaceuticals Corporation; and receives royalties from Elsevier and UpToDate.
Charles A. Leath III, MD, Panel Member, has disclosed that he is a scientific advisor for AbbVie Inc., and Clovis Oncology.
Joyce Liu, MD, Panel Member, has disclosed that she receives consulting fees/honoraria from Clovis Oncology and Tesaro, Inc.
Haider Mahdi, MD, MPH, Panel Member, has disclosed that he receives grant/research support from Puma Biotechnology, and received consulting fees/honoraria from Tesaro, Inc.
Daniela Matei, MD, Panel Member, has disclosed that she receives consulting fees/honoraria from and is a scientific advisor for Genentech/Roche, AstraZeneca Pharmaceuticals LP, and Radivin.
David M. O’Malley, MD, Panel Member, has disclosed that he receives grant/research support from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Exelixis Inc., Genentech, Inc., GlaxoSmithKline, ImmunoGen, Inc., Janssen Pharmaceutica Products, LP, Novartis Pharmaceuticals Corporation, Novocure, Agenus Inc., Ajinomoto Co, Inc., Array BioPharma Inc., ERGOMED Clinical Research Ltd, INC Research, Inc, Regeneron Pharmaceuticals, Inc., Tesaro, Inc., TRACON Pharmaceuticals, Inc. He receives consulting fees/honoraria from AbbVie Inc., AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, Inc., Ambry Genetics, and Tesaro, Inc. He is a scientific advisor for AbbVie Inc., AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, Inc., ImmunoGen, Inc., Janssen Pharmaceutica Products, LP, Myriad Genetic Laboratories, Inc., Novocure, Agenus Inc., Marker Therapeutics, Inc., OncoQuest Inc., and Regeneron Pharmaceuticals, Inc.
Richard T. Penson, MD, MRCP, Panel Member, has disclosed that he is a scientific advisor for AbbVie, Clovis Oncology, Janssen Oncology, NewLink Genetics, Roche, Inc., and Tesaro Inc.; is a scientific advisor for and received grant/research support from AstraZeneca Pharmaceuticals LP, Eisai Inc., Genentech, Merck & Co., Sutro Biopharma, and Vascular Biogenics Ltd.
Steven W. Remmenga, MD, Panel Member, has disclosed that he is a scientific advisor for TRICARE Humana.
Paul Sabbatini, MD, Panel Member, has disclosed that he receives grant/research support from Bristol-Myers Squibb.

To view all of the conflicts of interest for the panel, go to NCCN.org/disclosures/guidelinepanellisting.aspx.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour. 

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-19-010-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until August 10, 2020. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Accreditation Period

Course opens: 
08/10/2019
Course expires: 
08/10/2020

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing